Cost-effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand

Asian Biomedicine

Volumn 4, Issue 4, 2010, Pages 571-578

  Boonsawat, Watchara ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Asthma; Budesonide; Cost effectiveness analysis; Formoterol; Thailand

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; TERBUTALINE;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 77957952009     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: 10.2478/abm-2010-0072     Document Type: Article

References (32)

1. Vichyanond P, Kaewsomboon S, Ruangrak S, Visitsunthorn N, Cherdjirapong V, Pongsamart G, et al. Increasing prevalence of allergic diseases among Thai children: The ISAAC III results. J Allergy Clin Immunol. 2003; 111 (Suppl 2):S310
2. Trakultivakorn M, Sangsupawanich P, Vichyanond P. Time trends of the prevalence of asthma, rhinitis and eczema in Thai children-ISAAC (International Study of Asthma and Allergies in Childhood) phase three. J Asthma. 2007; 44:609-11
3. Vichyanond P, Jirapongsananuruk O, Visitsuntorn N, Tuchinda M. Prevalence of asthma, rhinitis and eczema in children from the Bangkok area using the ISAAC (International Study for Asthma and Allergy in Children) questionnaires. J Med Assoc Thai. 1998; 81: 175-84
4. Teeratakulpisarn J, Pairojkul S, Heng S. Survey of the prevalence of asthma, allergic rhinitis and eczema in schoolchildren from Khon Kaen, Northeast Thailand. an ISAAC study. International Study of Asthma and Allergies in Childhood. Asian Pac J Allergy Immunol. 2000; 18:187-94
5. Dejsomritrutai W, Nana A, Chierakul N, Tscheiguna J, Sompradeekul S, Rattanaumpawan P, et al. Prevalence of bronchial hyperresponsiveness and asthma in the adult population in Thailand. Chest. 2006; 129:602-9
6. Boonsawat W, Charoenphan P. Prevalence of asthma symptoms in adult in 4 cities of Thailand. Presented at Joint Scientific Meeting of Thoracic Soc Thailand, Malaysia Thoracic Soc and the Singapore Thoracic Soc. Bangkok, 2002, Bangkok
7. Boonsawat W, Charoenphan P, Kiatboonsri S, Wongtim S, Viriyachaiyo V, Photirat C, et al. Survey of asthma control in Thailand. Respirology. 2004; 9:373-8
8. Briggs AH, Bousquet J, Wallace M V, Busse WW, Clark TJH, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy. 2006; 61:531-6
9. de Asis ML, Greene R. A cost-effectiveness analysis of a peak flow-based asthma education and self-management plan in a high-cost population. J Asthma. 2004; 41:559-65
10. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/ formoterol compared with fluticasone in moderate-persistent asthma. Respir Med. 2006; 100:586-94
11. Franco R, Santos AC, do Nascimento HF, Souza-Machado C, Ponte E, Souza-Machado A, et al. Cost-effectiveness analysis of a state funded program for control of severe asthma. BMC Public Health. 2007; 7:82
12. Lord J, Ducharme FM, Stamp RJ, Littlejohns P, Churchill R. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma. BMJ. 1999; 319:1470-1
13. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004; 114:265-9
14. Persson U, Ghatnekar O. Cost-effectiveness analysis of inhaled corticosteroids in asthma: a review of the analytical standards. Respir Med. 2003; 97:1-11
15. Pinnock H, McKenzie L, Price D, Sheikh A. Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. Br J Gen Pract. 2005; 55:119-24
16. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007; 25:577-90
17. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2003; 112:1229-36
18. Chuesakoolvanich K. Cost of hospitalizing asthma patients in a regional hospital in Thailand. Respirology. 2007; 12:433-8
19. Visitsunthorn N, Durongpisitkul W, Uoonpan S, Jirapongsananuruk O, Vichyanond P. Medical charge of asthma care in admitted Thai children. J Med Assoc Thai. 2005; 88 (Suppl 8):S16-20
20. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005; 171:129-36
21. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007; 61:725-36
22. Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO 2003
23. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med. 2003; 22: 1955-76
24. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics. 1996; 9: 113-20
25. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York:Chapman & Hall; 1993
26. Estimated population for Thai Kingdom.Boonsawat W, Charoenphan P, Kiatboonsri S. Prevalence of asthma and rhinitis symptoms in adult in 4 cities of Thailand. Presented at 4th World Asthma Meeting, Bangkok, 2004
27. Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluations. In: Economic evaluation in health care-merging theory with practice. Drummond M, McGuire A, editors. New York: Oxford University Press; 2001
28. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy. 2005; 10:245-50
29. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. 2007; 62:1189-98
30. Chapman KR. Seretide for obstructive lung disease. Expert Opin Pharmacother. 2002; 3:341-50
31. Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Liu Z, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol Assess. 2008; 12:1-174
32. Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 2008; 12:1-254